DOI QR코드

DOI QR Code

Comorbidity Relationship to Outcome of Radical Cystectomy in Chinese: a Single Institution Study with the ACE-27 Comorbidity Index

  • Xuan, Zhu (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Zhong, Zhao-Hui (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Zhang, Xuan-Zhi (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Zhang, Lei (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Zhao, Xiao-Kun (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Lv, Chen (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Xu, Ran (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Ren, Wei-Gang (Urology Department, The Second Xiangya Hospital of Central South University) ;
  • Li, Song-Chao (Urology Department, The Second Xiangya Hospital of Central South University)
  • Published : 2012.03.31

Abstract

To determine the relationship between comorbidity and outcome after radical cystectomy in Chinese patients by using the Adult Comorbidity Evaluation (ACE)-27 index. Two-hundred-and-forty-six patients treated with radical cystectomy at the Second Xiangya Hospital of Central South University, Hunan Province, China between 2000 and 2010 were retrospectively analyzed. Medical records were reviewed for age, gender, delayed time of radical cystectomy, urinary diversion type, pelvic lymphadenectomy status, TNM stage, and pathological grade. Comorbidity information was assessed by the ACE-27 index. The outcome measurement was overall survival. Univariate and multivariate Cox proportional hazards regression analyses were used to determine the association between comorbidity and outcome. The study population consisted of 215 (87.40%) males and 31 (12.60%) females with a mean age of $62{\pm}11$ years. Median duration of follow-up was $47{\pm}31$ months. A total of 151 (61.38%) patents died during follow-up. Of those, 118 (47.97%) had at least one comorbidity. According to the ACE-27 scores, 128 (52.03%) patients had no comorbidity, 79 (32.11%) had mild, 33 (13.41%) had moderate, and 6 (2.45%) had severe comorbidities. Multivariate analysis indicated that moderate (p=0.002) and severe (p<0.001) comorbidity was significantly associated with decreased overall survival. In addition, age ${\geq}70$ years (p=0.002), delayed time of radical cystectomy >12 weeks (p=0.044), pelvic lymphadenectomy status (p=0.014), and TNM stage >T3 (p<0.001) were determined to be independent risk factors of overall survival. Increasing severity of comorbidity statistically correlated with decreased overall survival after radical cystectomy.

References

  1. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, et al (2006). Tobacco smoke and bladder cancer--in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 119, 2412-6. https://doi.org/10.1002/ijc.22169
  2. Brunocilla E, Pernetti R, Martorana G (2011). The role of pelvic lymph node dissection during radical cystectomy for bladder cancer. Anticancer Res, 31, 271-5.
  3. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol, 22, 1435-48. https://doi.org/10.1097/00000478-199812000-00001
  4. Extermann M (2000). Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol, 35, 181-200. https://doi.org/10.1016/S1040-8428(00)00090-1
  5. Fairey AS, Jacobsen NE, Chetner MP, et al (2009). Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database. J Urol, 182, 85-92. https://doi.org/10.1016/j.juro.2008.11.111
  6. Fisher MB, Svatek RS, Hegarty PK, et al (2009). Cardiac history and risk of post-cystectomy cardiac complications. Urology, 74, 1085-9. https://doi.org/10.1016/j.urology.2009.04.103
  7. Gore JL, Lai J, Setodji CM, et al (2009). Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results- Medicare analysis. Cancer, 115, 988-96. https://doi.org/10.1002/cncr.24052
  8. Hall SF (2006). A user's guide to selecting a comorbidity index for clinical research. J Clin Epidemiol, 59, 849-55. https://doi.org/10.1016/j.jclinepi.2005.11.013
  9. Hurle R, Naspro R (2010). Pelvic lymphadenectomy during radical cystectomy: a review of the literature. Surg Oncol, 19, 208-20. https://doi.org/10.1016/j.suronc.2009.05.004
  10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  11. Koppie TM, Serio AM, Vickers AJ, et al (2008). Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 112, 2384-92. https://doi.org/10.1002/cncr.23462
  12. Lund L, Jacobsen J, Clark P, et al (2010). Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. Urology, 75, 393-8. https://doi.org/10.1016/j.urology.2009.07.1320
  13. Madersbacher S, Hochreiter W, Burkhard F, et al (2003). Radical cystectomy for bladder cancer today-a homogenous series without neoadjuvant therapy. J Clin Oncol, 21, 690-6. https://doi.org/10.1200/JCO.2003.05.101
  14. Megwalu II, Vlahiotis A, Radwan M, Piccirillo JF, Kibel AS (2008). Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol, 53, 581-9. https://doi.org/10.1016/j.eururo.2007.10.069
  15. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT (2003). The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol, 169, 105-9.
  16. Nieder AM, Mackinnon JA, Huang Y, et al (2008). Floridabladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease. J Urol, 179, 491-5.
  17. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  18. Piccirillo JF, Feinstein AR (1996). Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer, 77, 834-42. https://doi.org/10.1002/(SICI)1097-0142(19960301)77:5<834::AID-CNCR5>3.0.CO;2-E
  19. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004). Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA, 291, 2441-7. https://doi.org/10.1001/jama.291.20.2441
  20. Prout GR Jr, Wesley MN, Yancik R (2005). Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer, 104, 1638-47. https://doi.org/10.1002/cncr.21354
  21. Shariat SF, Karakiewicz PI, Palapattu GS (2006). Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol, 176, 2414-22. https://doi.org/10.1016/j.juro.2006.08.004
  22. Sobin DH, Witteking (eds) (2002). TNM Classification of Malignant Tumors, 6th ed. Wiley-Liss, New York, 199-202.
  23. Stein JP, Lieskovsky G, Cote R (2001). Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol, 19, 666-75. https://doi.org/10.1200/JCO.2001.19.3.666